| In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial M Gejl, A Gjedde, L Egefjord, A Møller, SB Hansen, K Vang, A Rodell, ... Frontiers in aging neuroscience 8, 198350, 2016 | 379 | 2016 |
| Quantitative rates of brain glucose metabolism distinguish minimally conscious from vegetative state patients J Stender, R Kupers, A Rodell, A Thibaut, C Chatelle, MA Bruno, M Gejl, ... Journal of Cerebral Blood Flow & Metabolism 35 (1), 58-65, 2015 | 153 | 2015 |
| Blood-brain glucose transfer in Alzheimer’s disease: effect of GLP-1 analog treatment M Gejl, B Brock, L Egefjord, K Vang, J Rungby, A Gjedde Scientific reports 7 (1), 17490, 2017 | 130 | 2017 |
| Capillary dysfunction is associated with symptom severity and neurodegeneration in Alzheimer's disease RB Nielsen, L Egefjord, H Angleys, K Mouridsen, M Gejl, A Møller, ... Alzheimer's & Dementia 13 (10), 1143-1153, 2017 | 100 | 2017 |
| Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´ s disease-protocol for a controlled, randomized double-blinded trial. L Egefjord, M Gejl, A Møller, H Brændgaard, H Gottrup, O Antropova, ... brain 12, 14, 2012 | 90 | 2012 |
| Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes M Gejl, HM Søndergaard, C Stecher, BM Bibby, N Møller, HE Bøtker, ... The Journal of Clinical Endocrinology & Metabolism 97 (7), E1165-E1169, 2012 | 81 | 2012 |
| Regional cerebral effects of ketone body infusion with 3-hydroxybutyrate in humans: reduced glucose uptake, unchanged oxygen consumption and increased blood flow by positron … M Svart, LC Gormsen, J Hansen, D Zeidler, M Gejl, K Vang, J Aanerud, ... PLoS One 13 (2), e0190556, 2018 | 76 | 2018 |
| Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia M Gejl, L Egefjord, S Lerche, K Vang, BM Bibby, JJ Holst, A Mengel, ... Journal of Cerebral Blood Flow & Metabolism 32 (12), 2146-2152, 2012 | 54 | 2012 |
| Targeting amyloid-beta by glucagon-like peptide-1 (GLP-1) in Alzheimer's disease and diabetes AM Bak, L Egefjord, M Gejl, C Steffensen, CW Stecher, K Smidt, B Brock, ... Expert opinion on therapeutic targets 15 (10), 1153-1162, 2011 | 39 | 2011 |
| Experimental non-severe hypoglycaemia substantially impairs cognitive function in type 2 diabetes: a randomised crossover trial M Nilsson, N Jensen, M Gejl, ML Bergmann, H Storgaard, M Zander, ... Diabetologia 62, 1948-1958, 2019 | 35 | 2019 |
| Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain M Gejl, S Lerche, L Egefjord, B Brock, N Møller, K Vang, AB Rodell, ... Frontiers in neuroenergetics 5, 2, 2013 | 33 | 2013 |
| Glucagon-like peptide-1 analog, liraglutide, delays onset of experimental autoimmune encephalitis in lewis rats B DellaValle, GS Brix, B Brock, M Gejl, AM Landau, A Møller, J Rungby, ... Frontiers in Pharmacology 7, 433, 2016 | 32 | 2016 |
| At the Centennial of Michaelis and Menten, Competing Michaelis–Menten Steps Explain Effect of GLP‐1 on Blood–Brain Transfer and Metabolism of Glucose M Gejl, J Rungby, B Brock, A Gjedde Basic & clinical pharmacology & toxicology 115 (2), 162-171, 2014 | 32 | 2014 |
| Differences between long-acting insulins for the treatment of type 2 diabetes MG Jensen, M Hansen, B Brock, J Rungby Expert opinion on pharmacotherapy 11 (12), 2027-2035, 2010 | 28 | 2010 |
| Risk of cardiovascular disease: the effects of diabetes and anti-diabetic drugs—a nested case–control study M Gejl, J Starup-Linde, J Scheel-Thomsen, S Gregersen, P Vestergaard International Journal of Cardiology 178, 292-296, 2015 | 26 | 2015 |
| Oral administration of sitagliptin activates creb and is neuroprotective in murine model of brain trauma B DellaValle, GS Brix, B Brock, M Gejl, J Rungby, A Larsen Frontiers in pharmacology 7, 450, 2016 | 23 | 2016 |
| Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo-or hypoglycemia M Gejl, S Lerche, A Mengel, N Møller, BM Bibby, K Smidt, B Brock, ... PLoS One 9 (1), e83758, 2014 | 23 | 2014 |
| In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front … M Gejl, A Gjedde, L Egefjord, A Møller, SB Hansen, K Vang, A Rodell, ... DOI: https://doi. org/10.3389/fnagi, 108, 2016 | 22 | 2016 |
| Different mechanisms involved in liraglutide and glucagon‐like peptide‐1 vasodilatation in rat mesenteric small arteries M Bangshaab, A Gutierrez, KD Huynh, JS Knudsen, DDR Arcanjo, ... British journal of pharmacology 176 (3), 386-399, 2019 | 21 | 2019 |
| Effects of hypoglycaemia on working memory and regional cerebral blood flow in type 1 diabetes: a randomised, crossover trial M Gejl, A Gjedde, B Brock, A Møller, E van Duinkerken, HL Haahr, ... Diabetologia 61, 551-561, 2018 | 20 | 2018 |
Jørgen RungbyProfessor, Steno Diabetes Center Copenhagen, CPH, DenmarkVerified email at regionh.dk
